COGNATE BIOSERVICES, INC.;NORTHWEST BIOTHERAPEUTICS, INC.;REVLMMUNE, INC.;THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
发明人:
JAMES KELLY GANJEI,LINDA F. POWERS,LINDA M. LIAU,MARNIX LEO BOSCH,ROBERT M. PRINS
申请号：
BR112016010224
公开号：
BR112016010224A2
申请日:
2014.11.05
申请国别(地区):
BR
年份:
2018
代理人:
摘要：
The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
